Lupin unveils Rymti biosimilar Etanercept in Canada Ruchika Sharma5 May 2024 10:00 AM ISTMumbai: Global pharma major Lupin Limited has announced the launch of Rymti, Lupin's first biosimilar in Canada, through its partner Sandoz...
Conduct bridging CT, prove efficacy, safety: CDSCO Panel Tells Glenmark on Roflumilast Cream of additional strength, indication Dr. Divya Colin30 April 2024 6:00 PM ISTNew Delhi: Citing that Glenmark Limited should conduct bridging clinical trials to prove the efficacy and safety of the Roflumilast Cream 0.3%w/w...
USFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, Teva Ruchika Sharma17 April 2024 4:18 PM ISTReykjavik: Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., have announced that the U.S. Food and Drug...
Unlocking Insights: The real-world BrIDGE study on brodalumab effectiveness in psoriasis patients Medha Baranwal17 April 2024 7:45 AM ISTGreece: A large-scale study evaluating brodalumab for moderate-to-severe plaque psoriasis revealed significant improvements in patient outcomes.The...
Oral IL-23 inhibitor promising for treatment of moderate-to-severe plaque psoriasis: NEJM Medha Baranwal9 Feb 2024 10:00 AM ISTCanada: A recent study showed greater treatment efficacy with the interleukin-23-receptor antagonist peptide JNJ-77242113 after 16 weeks of once- or...
Experimental topical PDE4 inhibitor showed superior efficacy for atopic dermatitis, plaque psoriasis: JAMA Medha Baranwal12 Jan 2024 6:30 AM ISTUSA: A phase 2a study published in JAMA Dermatology revealed the superior efficacy of an experimental topical phosphodiesterase 4 (PDE4) inhibitor to...
Sun Pharma Ilumetri now included in category B of China National Reimbursement Drug List Ruchika Sharma14 Dec 2023 2:43 PM ISTILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
FDA approved Bimzelx for plaque psoriasis now commercially available Dr. Kamal Kant Kohli15 Nov 2023 7:15 PM ISTIn October US Food and Drug Administration had approved for plaque psoriasis. Bimzelx, an IL-17A and IL-17F inhibitor is now commercially available...
Bristol Myers Squibb Sotyktu long term data demonstrate durable efficacy, consistent safety for up to 3 years in moderate-to-severe Plaque Psoriasis Ruchika Sharma12 Oct 2023 12:50 PM ISTPrinceton: Bristol Myers Squibb has announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu...
Prove efficacy of Itolizumab for subcutaneous route: CDSCO panel Tells Biocon Biologics Dr. Divya Colin13 Sept 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Biocon...
Intas Pharma marketing authorization application for proposed biosimilar of Stelara accepted by EMA Ruchika Sharma15 July 2023 11:00 AM ISTDMB-3115 is a proposed biosimilar to Stelara which is a blockbuster drug developed by Janssen Biotech Inc. for plaque psoriasis, psoriatic arthritis,...
Tildrakizumab linked to improved outcomes in plaque psoriasis patients Jacinthlyn Sylvia10 July 2023 9:30 AM ISTAlmirall, a global biopharmaceutical company specializing in medical dermatology, has announced significant progress in the treatment of...
